varieti
virus
adenoviru
ad
poxviru
explor
vaccin
gene
deliveri
vector
prevent
andor
treatment
variou
human
diseas
among
viral
vector
recombin
ad
prefer
promis
deliveri
system
sinc
viru
exhibit
rel
low
cytotox
larg
clone
capac
replic
high
titr
abil
infect
divid
undivid
cell
recent
adenovir
vector
found
effect
mucos
vaccin
due
natur
tropism
mucos
surfac
note
howev
main
cellular
receptor
ad
coxsackieviru
adenoviru
receptor
car
readili
detect
wide
rang
human
tissu
may
potenti
undesir
consequ
find
prompt
sever
group
conduct
variou
genet
modif
ad
improv
deliveri
effici
andor
minim
rel
random
distribut
inject
ad
retarget
ad
dendrit
cell
dc
dc
antigenpres
cell
play
crucial
role
establish
antigenspecif
adapt
immun
respons
therefor
stimul
potent
immun
respons
possibl
dcbase
strategi
immunotherapi
immunoprotect
cancer
infecti
diseas
transplant
vigor
investig
past
sever
year
howev
dc
defici
express
car
receptor
present
challeng
effect
transduct
cell
ad
addit
also
concern
cytopath
effect
highdos
ad
dc
could
compromis
clinic
valu
recombin
ad
overcom
limit
retarget
deliveri
strategi
via
modif
tropism
viru
develop
better
transduct
dc
one
approach
involv
genet
modif
fiberknob
protein
ad
target
surfac
intergrin
dc
anoth
approach
target
surfac
receptor
dc
sinc
receptor
may
play
essenti
role
promot
dc
activ
antigen
present
end
virus
usual
complex
bispecif
adaptor
molecul
compris
either
antiad
singlechain
antibodi
extracellular
domain
car
target
ligand
mark
improv
transduct
effici
enhanc
immun
respons
transgen
deliv
variou
target
ad
vector
report
other
us
systemat
analys
biodistribut
toxic
immun
respons
follow
variou
administr
rout
remain
poorli
document
uncertainti
also
remain
respect
form
deliveri
dnaand
proteinbas
system
instanc
even
though
consist
shown
enhanc
cellular
immun
respons
role
humor
respons
remain
unclear
report
suggest
increas
antibodi
respons
other
report
adjuv
effect
lack
knowledg
area
could
substanti
hinder
transit
laboratori
investig
clinic
applic
gene
deliveri
genet
vaccin
studi
focus
vivo
analys
biodistribut
immunogen
modifi
ad
complex
adaptor
protein
fusion
protein
compris
human
ad
receptor
car
fuse
mous
via
trimer
motif
report
previous
significantli
enhanc
vitro
gene
transfer
dc
express
demonstr
modifi
ad
denot
tad
report
irrespect
rout
administr
profoundli
alter
pattern
biodistribut
immun
respons
transgen
potenti
mechan
underli
differ
unmodifi
target
vector
discuss
show
previous
could
direct
ad
dc
addit
also
found
mous
bone
marrowderiv
dc
stimul
complex
result
elev
level
matur
marker
ia
prior
initi
biodistribut
studi
balbc
mice
first
test
whether
mab
could
prevent
vitro
gene
transfer
tadluc
express
luciferas
gene
conjug
end
adluc
conjug
describ
previous
use
transduc
human
dc
presenc
absenc
compar
unmodifi
ad
rel
luciferas
activ
ad
higher
addit
ng
ng
ng
figur
respect
reaction
four
replic
experi
repeat
three
time
similar
find
importantli
addit
mg
mab
precomplex
ad
larg
prevent
enhanc
luciferas
activ
premix
mg
normal
mous
immunoglobulin
ig
g
show
inhibit
luciferas
activ
also
control
ad
precomplex
ng
bovin
serum
albumin
bsa
result
enhanc
luciferas
activ
transduc
cell
result
confirm
enhanc
gene
transduct
human
murin
dc
ad
complex
mediat
receptor
next
determin
whether
tad
could
still
transduc
dc
presenc
adneutr
antibodi
toward
end
infect
human
peripher
bloodderiv
dc
complex
presenc
adneg
adposit
ascit
fluid
collect
ovarian
cancer
patient
phase
gene
therapi
clinic
trial
ascit
patient
day
ad
administr
shown
high
adneutr
antibodi
titr
ascit
patient
b
day
ad
administr
none
furthermor
abil
ascit
neutral
ad
infect
lack
neutral
capabl
ascit
previous
document
studi
direct
rapid
captur
vector
liver
thymu
lung
follow
iv
administr
tad
encod
firefli
luciferas
report
gene
tadluc
inject
balbc
mice
intraven
iv
analysi
tissu
distribut
total
vp
viral
particl
ad
chosen
ad
tad
sinc
excess
amount
ad
could
satur
tissu
macrophag
mice
follow
system
administr
result
nonreceptormedi
process
tad
prepar
pfu
vp
ad
complex
mg
equival
ng
pfu
ad
chose
ratio
ad
sinc
ng
suffici
complex
ad
enhanc
transduct
vitro
figur
agreement
report
iv
administr
ad
detect
day
wide
rang
tissu
liver
spleen
express
highest
luciferas
activ
day
follow
mesenter
lymph
node
visibl
cluster
lymph
node
insid
periton
caviti
heart
colon
other
figur
yet
notic
alter
biodistribut
observ
tadluc
figur
addit
predomin
disposit
liver
spleen
virus
also
effect
captur
thymu
lung
day
figur
follow
intraderm
id
administr
high
level
luciferas
express
detect
skin
surround
inject
site
local
drain
lymph
node
inguin
adluc
tadluc
expect
luciferas
activ
tadluc
administr
significantli
lower
adluc
time
lower
sinc
tadluc
could
get
cell
express
luciferas
gene
figur
b
consist
result
shown
figur
clearli
viru
detect
organ
tissu
suggest
virus
process
near
inject
site
site
local
drain
lymph
node
littl
spillov
viru
circul
prevent
inadvert
infect
brain
attenu
local
inflammatori
reaction
lung
follow
administr
follow
intranas
deliveri
adluc
gene
transfer
ad
variou
organstissu
inject
figur
note
express
level
luciferas
brain
high
follow
adluc
administr
figur
second
one
detect
lung
clearli
infect
brain
larg
ablat
use
tadluc
infect
tissu
lung
heart
thymu
colon
muscl
mesenter
lymph
node
figur
b
suggest
carmedi
inadvert
infect
brain
nonmodifi
ad
interpret
support
observ
precomplex
adluc
bsa
prevent
brain
infect
figur
interestingli
signific
differ
viru
deposit
tadluc
adluc
heart
observ
follow
administr
figur
b
observ
differ
follow
iv
inject
show
heart
took
adluc
tadluc
follow
iv
administr
figur
definit
explan
find
plausibl
howev
sinc
heart
close
proxim
lung
tadluc
could
gain
access
easili
heart
follow
deliveri
iv
rout
tail
vein
high
level
luciferas
activ
lung
follow
administr
prompt
us
conduct
histolog
examin
lung
compar
control
mice
inject
buffer
figur
sever
affect
area
airway
epitheli
cell
demonstr
mildtomoder
damag
slough
reveal
exagger
inflammatori
reaction
lung
figur
panel
c
e
reason
visibl
damag
airway
epitheli
cell
layer
adnp
adluc
could
due
intrins
properti
np
strong
immunogen
sever
acut
respiratori
syndrom
sar
patient
suggest
see
discuss
note
addit
denot
tadnp
excess
infiltr
inflammatori
cell
damag
epitheli
cell
abolish
figur
panel
taken
togeth
significantli
alter
pattern
biodistribut
ad
complex
observ
follow
iv
administr
attenu
inadvert
infect
brain
aggrav
local
inflamm
demonstr
airway
lung
follow
administr
final
none
ad
prepar
unconjug
conjug
irrespect
administr
rout
result
detect
sign
systemat
toxic
follow
analys
variou
blood
biomark
blood
chemistri
pertin
vital
organ
kidney
heart
liver
data
shown
even
though
visibl
damag
airway
epitheli
cell
found
follow
administr
adnp
also
conduct
immunohistolog
examin
avail
lung
tissu
use
antibodi
luciferas
one
surfac
marker
dc
preliminari
result
suggest
tadluc
mainli
found
cell
adluc
restrict
cell
supplementari
figur
clearli
vigor
investig
need
identifi
cell
type
also
express
elicit
sustain
agspecif
cellular
immun
respons
determin
adjuv
target
effect
ad
express
sarscov
np
protein
adnp
compar
viru
complex
tadnp
follow
either
id
administr
tadluc
serv
baselin
control
chose
amount
viru
use
biodistribut
experi
thirti
day
postprim
mice
boost
splenocyt
isol
day
post
boost
determin
interferong
ifng
administr
ifng
specif
sarscov
np
increas
mice
immun
either
adnp
tadnp
compar
control
mice
receiv
adluc
howev
note
day
boost
level
ifng
mice
receiv
tadnp
substanti
higher
immun
adnp
suggest
sustain
respons
use
figur
b
furthermor
enhanc
agspecif
host
immun
respons
also
observ
inject
rout
figur
collect
data
reveal
elicit
sustain
agspecif
cellular
immun
respons
delay
agspecif
humor
respons
reduc
igg
ratio
specif
igg
iga
antibodi
np
protein
determin
elisa
measur
antibodi
present
sera
trachea
lung
mucos
antibodi
surprisingli
level
igg
iga
sera
follow
tadnp
administr
id
significantli
lower
adnp
immun
via
id
administr
rout
figur
b
next
determin
titr
igg
iga
present
sera
trachealung
lavag
follow
administr
found
humor
respons
similar
id
rout
shown
figur
igg
iga
titr
mice
immun
tadnp
significantli
lower
adnp
especi
day
postboost
note
howev
antibodi
titr
reach
similar
level
day
postboost
follow
administr
figur
addit
similar
find
term
agspecif
antibodi
respons
differ
transgen
luciferas
also
obtain
use
tadluc
supplementari
figur
data
collect
suggest
reduct
agspecif
humor
respons
link
ident
transgen
use
conjunct
adenovir
vector
determin
rel
ratio
deliv
either
unmodifi
vector
end
horseradish
peroxidas
hrp
conjug
antimous
use
place
hrpconjug
antimous
igg
elisa
shown
figur
reduc
ratio
observ
use
target
vector
also
observ
lower
level
figur
data
addit
increas
level
cytokin
ifn
figur
suggest
immun
might
elicit
immun
respons
determin
whether
conjug
ad
could
affect
gener
antiad
antibodi
respons
end
analys
adspecif
iga
lung
lavag
collect
mice
immun
tadnp
administr
elisa
use
sucros
gradientpurifi
ad
viral
lysat
deriv
ade
ad
express
differ
exogen
gene
antigen
place
np
protein
elisa
shown
figur
antibodi
respons
ad
protein
markedli
suppress
mice
immun
tadnp
compar
follow
immun
adnp
furthermor
data
also
provid
addit
evid
decreas
agspecif
antibodi
respons
link
use
vector
ident
transgen
agreement
figur
supplementari
figur
varieti
macromolecul
immunostimulatori
immunomodulatori
properti
explor
recent
year
molecular
adjuv
enhanc
effici
genet
vaccin
andor
gene
therapi
preclin
clinic
set
member
tumor
necrosi
factor
superfamili
attract
candid
sinc
potent
activ
dc
express
well
known
profession
antigenpres
cell
numer
studi
report
literatur
reveal
administr
model
antigen
togeth
dna
construct
express
fusion
protein
compris
antigen
result
substanti
enhanc
cellular
type
humor
type
ii
immun
respons
three
line
evid
prompt
us
conduct
current
studi
first
note
data
lack
systemat
analys
vector
term
biodistribut
toxic
immunogen
second
although
enhanc
immun
respons
observ
knowledg
remain
poor
regard
outcom
follow
altern
rout
administr
noteworthi
ad
found
effect
mucos
deliveri
due
natur
tropism
ad
mucos
surfac
third
although
cellular
immun
respons
appear
markedli
improv
use
substitut
hrpconjug
antimous
igg
elisa
describ
serum
sampl
deriv
mice
day
post
boost
similar
result
obtain
day
boost
data
shown
report
headtohead
comparison
unmodifi
ad
tad
conduct
term
biodistribut
immun
respons
expect
vitro
transduct
assay
adaptor
protein
compris
human
ad
receptor
car
fuse
mous
notic
alter
pattern
tissu
distribut
virus
vivo
predomin
deposit
virus
detect
liver
spleen
thymu
lung
figur
alter
biodistribut
pattern
unlik
due
detarget
car
sinc
modifi
adenovir
vector
ablat
car
shown
overal
reduc
effici
gene
express
tissu
chang
biodistribut
pattern
contrast
found
express
level
transgen
deliv
two
vector
compar
certain
tissu
liver
spleen
iv
administr
furthermor
observ
thymu
lung
took
tad
ad
fact
also
differ
detarget
car
follow
iv
administr
data
suggest
alter
biodistribut
pattern
due
target
rather
detarget
car
higher
express
tad
lung
may
suggest
like
presenc
abund
cell
organ
shown
epithelialendotheli
cell
antigenpres
cell
dc
activ
monocyt
b
cell
presenc
cell
lung
may
suggest
innat
host
defenc
well
place
fend
invad
pathogen
air
interest
normal
circumst
lung
major
tissu
organ
take
unmodifi
ad
follow
intravascular
administr
figur
pulmonari
intravascular
macrophag
howev
take
unexpectedli
high
amount
viru
anim
hepat
disord
cirrhosi
result
sever
pulmonari
patholog
clearli
better
understand
biodistribut
unmodifi
modifi
ad
vector
import
given
knowledg
help
understand
clearanc
viru
vector
well
identifi
tissuesorgan
could
predispos
advers
event
cours
gene
therapi
biodistribut
tad
follow
administr
result
comparison
ad
tad
follow
administr
appear
inadvert
infect
central
nervou
system
cn
mediat
car
receptor
receptor
v
b
integrin
heparin
sulphat
glycosaminoglycan
shown
mediat
entri
ad
discuss
inadvert
infect
cn
live
viral
vector
could
safeti
concern
vector
given
moreov
observ
visibl
lesion
lung
especi
airway
epitheli
cell
mice
receiv
unmodifi
adnp
deleteri
effect
adnp
appar
caus
strong
local
inflammatori
reaction
suggest
massiv
infiltr
lymphocyt
macrophag
yet
exagger
local
inflammatori
reaction
observ
mice
receiv
tadnp
time
definit
explan
mark
differ
local
inflammatori
reaction
adnp
tadnp
yet
interest
note
other
report
sarscov
np
protein
use
studi
model
antigen
could
alter
cellular
signal
transduct
pathway
stimul
proinflammatori
cytokin
product
andor
even
cell
death
therefor
excess
inflammatori
reaction
toxic
induc
adnp
like
due
combin
immunostimulatori
immunopatholog
effect
ad
infect
np
protein
notion
also
support
observ
adluc
fail
induc
magnitud
local
inflammatori
reaction
figur
substanti
increas
product
agspecif
ifng
use
tadnp
later
time
point
larg
expect
sinc
ligat
suggest
promot
activ
antigenpres
function
dc
express
well
known
initi
immun
respons
interestingli
earli
time
point
level
agspecif
ifng
rather
compar
unmodifi
target
vector
group
later
time
point
howev
level
two
cytokin
remain
elev
use
target
vector
accompani
lower
level
reduc
ratio
whether
sustain
ifng
respons
use
target
vector
due
better
develop
memori
tcell
compart
would
requir
investig
note
howev
stimul
shown
facilit
develop
memori
tcell
compart
experiment
condit
markedli
delay
agspecif
mucos
system
antibodi
respons
use
adaptor
protein
somewhat
surpris
given
fact
report
literatur
suggest
activ
cellular
humor
immun
respons
antigen
deliv
form
protein
dna
construct
howev
find
partial
agreement
two
studi
demonstr
lack
stimulatori
effect
product
agspecif
antibodi
unlik
bias
immun
respons
report
link
ident
transgen
similar
observ
sustain
ifng
reduc
antibodi
titr
later
time
point
observ
tadnp
tadluc
supplementari
figur
addit
use
tad
result
decreas
antibodi
level
adenovir
protein
figur
howev
sinc
transgen
current
studi
sarscov
np
firefli
luciferas
intracellular
protein
remain
determin
whether
tad
encod
secret
transgen
would
result
similar
pattern
immun
respons
note
howev
other
recent
report
differ
system
solubl
protein
secret
protein
fail
gener
stronger
antibodi
respons
compar
untarget
secret
protein
time
think
varieti
factor
could
ascrib
differ
result
respect
pattern
immun
respons
among
target
adenoviru
cell
huang
et
al
variou
group
one
might
due
differ
vector
system
understood
studi
employ
live
viral
vector
conjunct
system
design
deliv
antigen
form
dna
plasmid
solubl
protein
viruslik
particl
second
bias
immun
respons
might
due
much
lower
level
transgen
express
use
tad
vector
site
bodi
receiv
viral
vector
instanc
compar
ad
less
transgen
express
inject
site
skin
figur
b
observ
follow
id
inject
tad
less
lung
day
administr
figur
b
gener
agspecif
humor
respons
preferenti
elicit
respons
smaller
amount
antigen
compar
cellular
immun
respons
third
tadinduc
bias
immun
respons
could
tad
interact
b
cell
previou
report
document
ligat
could
lead
larg
posit
growth
outcom
rest
b
cell
inhibit
growth
ig
product
activ
b
cell
also
known
given
find
caution
appear
warrant
consid
target
moieti
adenovir
vector
genet
immun
induct
humor
immun
respons
crucial
neutral
antibodi
pathogen
nevertheless
therapeut
manipul
facilit
bias
skew
immun
respons
could
benefici
clinic
applic
instanc
type
immun
respons
predomin
antibodi
reaction
may
associ
certain
immunopatholog
complic
allergi
asthma
autoimmun
diseas
therebi
redirect
immun
respons
therapeut
manipul
toward
bias
immun
respons
suppress
antibodi
respons
could
help
revers
medic
condit
relat
certain
immunopatholog
complic
furthermor
enhanc
cellular
immun
respons
well
known
play
critic
role
elimin
contain
certain
intracellular
pathogen
cancer
final
preliminari
data
present
report
effici
vitro
gene
transduct
tad
even
presenc
antiad
neutral
antibodi
lower
level
antibodi
ad
viral
protein
vivo
might
also
help
allay
one
major
concern
associ
preexist
immun
ad
current
conduct
indepth
vivo
studi
address
issu
mab
recombin
human
granulocytemacrophag
colonystimul
factor
rhgmcsf
elispot
kit
variou
control
includ
ifng
purchas
r
system
minneapoli
mn
usa
brightglo
luciferas
assay
system
obtain
promega
madison
wi
usa
unless
specifi
antibodi
peroxidaseconjug
secondari
antibodi
purchas
cedarlan
lab
burlington
ontario
canada
adaptor
protein
fusion
protein
consist
human
ad
receptor
car
fuse
mous
via
trimer
motif
construct
use
target
ad
vector
mous
dc
express
purifi
supernat
stabl
cell
transfect
express
vector
product
purif
describ
previous
briefli
stabl
cell
line
produc
secret
protein
cultur
dmem
medium
supplement
fetal
calf
serum
mm
lglutamin
mg
ml
g
mg
ml
gentamicin
sulphat
medium
cell
cultur
collect
protein
precipit
addit
equal
volum
coldsatur
ammonium
sulphat
precipit
collect
centrifug
dissolv
origin
medium
volum
phosphatebuff
salin
pb
follow
dialysi
pb
recombin
protein
purifi
dialys
protein
solut
immobil
metal
affin
chromatographi
use
cobaltimmobil
talon
affin
resin
clontech
mountain
view
ca
usa
puriti
adaptor
protein
confirm
coomassi
blue
stain
western
blot
transgen
clone
adenovir
transfer
vector
vector
express
sarscov
np
use
model
antigen
isogen
control
vector
express
luciferas
gene
construct
similarli
replic
defect
recombin
ad
gener
construct
transfer
vector
describ
transgen
express
recombin
ad
confirm
luciferas
activ
assay
western
blot
analysi
antisar
nprotein
antibodi
ad
particl
purifi
cscl
gradient
centrifug
titrat
plaqueform
unit
pfu
per
ml
use
adenox
rapid
titer
kit
accord
manufactur
instruct
bd
bioscienc
san
jose
ca
usa
myeloid
dc
obtain
allcel
emeryvil
ca
usa
monocytederiv
cell
addit
surfac
marker
includ
hldr
previous
report
elev
level
matur
marker
dc
treat
ad
consist
studi
show
stimul
could
facilit
dc
matur
dc
cultur
medium
contain
rhgmcsf
cell
per
well
plate
day
prior
subject
treatment
ad
prepar
tadluc
encod
luciferas
gene
conjug
infect
dc
vitro
describ
previous
brief
ad
express
luciferas
gene
adluc
premix
adaptor
protein
incub
min
use
infect
dc
pfu
per
cell
day
infect
cell
harvest
measur
luciferas
activ
use
brightglo
luciferas
assay
system
femal
balbc
mice
purchas
charl
river
lab
montreal
quebec
canada
anim
experi
conduct
accord
guidelin
protocol
anim
experi
health
canada
mice
maintain
laminar
airflow
cabinet
pathogenfre
condit
use
week
age
total
pfu
viral
particl
ad
suspend
ml
pb
per
mous
administr
use
syring
needl
iv
tail
veil
intraderm
id
inguin
rout
control
mice
inject
ml
pb
prepar
ad
complex
describ
previous
brief
amount
ad
mix
mg
ng
pfu
ad
ml
pb
incub
min
mice
kill
day
administr
ad
tissu
collect
subsequ
analys
biodistribut
level
luciferas
activ
normal
protein
concentr
determin
five
mice
use
group
patholog
examin
tissu
use
hematoxylin
eosin
stain
method
conduct
use
standard
procedur
determin
adjuv
effect
nonmodifi
ad
express
sarscov
np
protein
adnp
compar
viru
complex
tadnp
follow
either
id
administr
tadluc
serv
baselin
control
chose
amount
viru
biodistribut
experi
immun
five
mice
prime
vp
adnp
tadnp
tadluc
neg
control
thirti
day
post
administr
mice
boost
splenocyt
isol
day
post
boost
determin
ifng
splenocyt
isol
mous
spleen
grind
frost
end
two
microscop
slide
slide
rins
ml
rpmi
medium
collect
cell
afterward
cell
suspens
pass
fine
nylon
mesh
obtain
singl
cell
suspens
spleen
piec
gentli
mash
rubber
end
syring
plunger
second
filtrat
perform
pipet
ml
suspens
dispers
cell
fresh
nylon
mesh
cell
strainer
conic
tube
ice
procedur
repeat
addit
wash
ml
medium
splenic
capsul
turn
white
time
total
volum
cell
suspens
brought
ml
medium
cell
pellet
obtain
centrifug
g
min
ml
nh
cl
solut
use
lyse
red
blood
cell
tube
gentli
roll
hand
min
room
temperatur
follow
addit
ml
chill
rpmi
medium
pass
cell
anoth
layer
nylon
mesh
cell
collect
centrifug
g
min
pellet
gentli
resuspend
cell
per
ml
cell
per
ml
rpmi
contain
heatinactiv
fetal
bovin
serum
presenc
purifi
sarscov
np
mg
ml
stimul
agspecif
cytokin
stimul
np
splenocyt
deriv
control
anim
receiv
adluc
result
detect
product
cytokin
background
subsequ
experi
conduct
presenc
mg
ml
np
cell
use
ml
per
well
elispot
assay
use
procedur
provid
supplier
r
system
determin
agspecif
antibodi
respons
igg
ratio
elisa
conduct
determin
titr
antibodi
sarscov
np
protein
end
nunc
plate
coat
ml
np
protein
mg
ml
mm
carbon
buffer
ph
incub
overnight
well
wash
five
time
pb
follow
addit
block
buffer
compris
pb
bsa
incub
h
block
buffer
remov
follow
addit
sampl
serum
wash
fluid
lung
mice
plate
incub
h
afterward
secondari
antibodi
peroxidaseconjug
goat
antimous
igg
igm
iga
ad
concentr
recommend
supplier
cedarlan
lab
follow
addit
incub
h
plate
wash
five
time
ophenylenediamin
dihydrochlorid
opd
ad
colorimetr
develop
posit
control
mous
antisar
monoclon
antibodi
purchas
bd
pharmingen
san
diego
ca
usa
cutoff
defin
mean
five
neg
sampl
unimmun
control
plu
two
sd
determin
rel
level
transgen
np
specif
igg
subclass
antimous
conjug
hrp
cedarlan
lab
substitut
antimous
igghrp
prior
addit
opd
colorimetr
develop
result
present
statist
comparison
conduct
use
twotail
student
ttest
consid
signific
